Aratana Therapeutics Appoints Craig Tooman to Board of Directors
Published: May 09, 2012
KANSAS CITY, Kan. and NEW YORK, May 9, 2012 /PRNewswire/ -- Aratana Therapeutics, an animal health company developing innovative medicines for companion animals, has announced the appointment of Craig Tooman, to its Board of Directors.
During his distinguished career, Mr. Tooman has held various senior positions in the pharmaceutical industry in international finance, sales, market research, business intelligence, strategic business management, and investor relations. After nearly a decade with Pharmacia & Upjohn (now Pfizer), Mr. Tooman moved to the biotechnology industry.
Mr. Tooman has made substantial contributions to companies including Ilex Oncology, which was sold to Genzyme Corporation for $1.1 billion; Enzon Pharmaceuticals and Ikaria. Mr. Tooman has recently been appointed CEO of Avanzar Medical, and he has been named entrepreneur-in-residence by the Cancer Prevention and Research Institute of Texas.
"Craig's exceptional track record guiding the evolution of different types of life sciences companies, his experience not just with finance but with all the disciplines that create a company's growth potential, and his ability to communicate with the financial community are skills Aratana will draw on extensively as we continue to develop new medicines to address unmet needs in companion animal health," says Board of Directors Chair Dr. Steven St. Peter.
Mr. Tooman has a Bachelor of Arts degree in economics with a minor in Japanese Language and a concentration in International Finance from Kalamazoo College. He received his MBA in Finance from the University of Chicago.
"Aratana's business model is unique and compelling in the animal health industry, and I believe the team guiding the company is exceptional," Mr. Tooman says. "I look forward to serving on the Board of Directors and helping shape the future of this very exciting enterprise."
About Aratana Therapeutics
Aratana Therapeutics is an animal health drug development company uniquely positioned to deliver high quality new medicines for unmet needs in animal health. Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then out-licenses to or partners with major animal health companies for commercialization. For more information, please visit www.aratanatherapeutics.com.
Contact: Dr. Linda Rhodes, CEO (firstname.lastname@example.org), 732-895-5420
SOURCE Aratana Therapeutics